RNS Number : 6269A
Shield Therapeutics PLC
30 September 2020

Shield Therapeutics plc
("Shield" or the "Group")

Block Listing 6 Monthly Return

Date: 30 September 2020

Name of *applicant*:		SHIELD THERAPEUTICS PLC		
Name of scheme:		Shield Therapeutics Retention Share Plan		
Period of return:	From:	06 March 2020	To:	30 September 2020
Balance of unallotted securities under scheme(s) from previous return:		54,219		
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL		
Less: Number of *securities* issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL		
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		54,219		

Name of *applicant*:		SHIELD THERAPEUTICS PLC		
Name of scheme:		Shield Therapeutics plc 2016 Company Share Option Plan		
Period of return:	From:	06 March 2020	To:	30 September 2020
Balance of unallotted securities under scheme(s) from previous return:		388,079		
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL		
Less: Number of *securities* issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL		
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		388,079		

Name of *applicant*:		SHIELD THERAPEUTICS PLC		
Name of scheme:		The Shield Therapeutics plc 2016 Long Term Incentive Plan		
Period of return:	From:	06 March 2020	To:	30 September 2020

Balance of unallotted securities under scheme(s) from previous return:	171,883
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	NIL
Less: Number of *securities* issued/allotted under scheme(s) during period (see LR3.5.7G):	NIL
Equals: Balance under scheme(s) not yet issued/allotted at end of period:	171,883

Name of *applicant*:		SHIELD THERAPEUTICS PLC		
Name of scheme:		Shield Therapeutics Retention and Performance Share Plan		
Period of return:	From:	06 March 2020	To:	30 September 2020
Balance of unallotted securities under scheme(s) from previous return:		1,885,819		
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL		
Less: Number of *securities* issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL		
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		1,885,819		

Name of contact:	Lucy Huntington-Bailey
Telephone number of contact:	+44 (0) 191 511 8500

For further information please contact:

Shield Therapeutics plc www.shieldtherapeutics.com
Tim Watts, Chief Executive Officer +44 (0)20 7186 8500
Lucy Huntington-Bailey, General Counsel and Company Secretary +44 (0) 19 1511 8500

Nominated Advisor and Broker
Peel Hunt LLP
James Steel/Dr Christopher Golden +44 (0)20 7418 8900

Joint Broker
finnCap Ltd +44 (0)20 7220 0500
Geoff Nash/Matt Radley/Alice Lane

Financial PR & IR Advisor
Walbrook PR +44 (0)20 7933 8780 or shield@walbrookpr.com

Paul McManus/Lianne Cawthorne +44 (0)7980 541 893 / +44 (0)7584 391 303

About Shield Therapeutics plc

Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru is commercialised in the UK and Europe by Norgine B.V. and the Company is currently in the process of selecting a commercialisation partner for the US market. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.

For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLREAANEDFXEEFA